Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Before Patrick Daly was tapped as chairman of AdvaMed’s Accel unit, which represents emerging medical device companies, the CEO of Cohera Medical sat down with MassDevice.com Executive Editor Brad Perriello at DeviceTalks Raleigh.
Daly, who founded the absorbable surgical adhesives and sealants company in 2006, has led 4 funding rounds totaling $75M in capital and brought Cohera Medical’s 1st product, TissuGlu, through the FDA’s stringent pre-market approval process. A 2nd product, Sylys, was the 1st medical device selected for the federal watchdog agency’s Expedited Access Protocol for breakthrough products. Read more
Boston Scientificsaid it launched its Axios stent and electrocautery delivery system designed to aid in the management of 2 serious complications from pancreatitis using a minimally invasive endoscopic approach.
The newly cleared Axios device has indications for endoscopic management of pancreatic pseudocysts and certain types of walled-off pancreatic necrosis, Marlborough, Mass.-based Boston Scientific said. The company added that the conditions represent 2 types of pancreatic fluid collections that occur in 5%-16% of patients with acute pancreatitis and 20%-40% of patients with chronic pancreatitis. Read more
Acutus Medical said that it closed a Series C funding round worth $75 million for the AcQMap 3D cardiac mapping technology it’s developing – including a contribution from an unnamed strategic investor.
Carlsbad, Calif.-based Acutus said participants in the round included new backers Deerfield Management, Xeraya Capital and the undisclosed strategic; prior investor Advent Life Sciences also participated. Read more
Abiomed said that it came to terms with the FDA over the indications for use for its Impella line of cardiac assist devices and doesn’t believe it will have to appear before 1 of the agency’s advisory panels.
Danvers, Mass.-based Abiomed said the federal safety watchdog agreed on the indication for treating patients in cardiogenic shock after a heart attack or cardiac surgery with its Impella 2.5, Impella CP, Impella 5.0 and Impella LD devices. Read more
Medtronic is planning to move a pair of product lines from a plant in Colorado to other facilities, a spokesman told MassDevice.com.
Fridley, Minn.-based Medtronic acquired the lines when it paid $50 billion for Covidien in January 2015. Spokesman John Jordan told us that the plant in Boulder, Colo., makes surgical energy return pads and electro-surgical pencils. Read more